Physician profile
David C Lu
NPI 1396716064
$3,703.16
in general payments reported to CMS, 2019-2025
14 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $254 · 2021: $534 · 2022: $980 · 2023: $771 · 2024: $617 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,879.01 | 2022-2025 | Envista Mx60 Iol, Amvisc, Vyzulta |
| Abbvie INC. | $339.76 | 2023-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $318.26 | 2019-2021 | |
| New World Medical,INC. | $302.43 | 2022-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Allergan, INC. | $208.33 | 2020-2022 | |
| Alcon Vision LLC | $148.56 | 2021 | |
| Aerie Pharmaceuticals, INC. | $124.12 | 2019 | |
| Mallinckrodt Hospital Products INC. | $119.89 | 2020 | |
| Sun Pharmaceutical Industries INC. | $87.72 | 2023-2024 | Cequa |
| Carl Zeiss Meditec, INC. | $58.44 | 2021 | |
| Dompe US, INC. | $42.17 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $34.33 | 2022-2023 | |
| Coopervision INC. | $20.89 | 2023 | Myday Contact Lens |
| Thea Pharma INC. | $19.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.